Euphrates Vascular is a Medical Device company aimed at becoming the disruptive market leader in treating vascular occlusions related to vascular disease. Our early focus is in the $3.5B Limb Ischemia market. Technologies will platform into Ischemic Stroke, Coronary, Wound Care, Dialysis, Interventional Oncology, and Orthopedic markets. Our inaugural ICHOR system is 510(k0 cleared to penetrate the peripheral arterial / venous market by replicating what works well in a surgical embolectomy, but in a 7F percutaneous system. ICHOR will treat organized thrombus and acute occlusions with superiority. The Pulse NanoMED technology (size of red blood cells) will initially seek indications for Chronic Total Occlusion (CTO) “crossing” and “distal reperfusion”. Iron Nano particles under the influence of an external magnet allows for CTO crossing and access to the smallest vessels (Brain or Foot) opening news ways to treat occlusions. Indications will expand into micro atherectomy, thrombolysis, stroke and wound care and will completely change our approach to a wide range of occlusions.